| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Migraine Disorders | 129 | 2024 | 1713 | 16.710 |
Why?
|
| Migraine with Aura | 26 | 2022 | 204 | 5.100 |
Why?
|
| Stroke | 84 | 2023 | 9742 | 4.080 |
Why?
|
| Migraine without Aura | 15 | 2021 | 82 | 3.640 |
Why?
|
| Headache | 17 | 2022 | 1262 | 3.090 |
Why?
|
| Restless Legs Syndrome | 10 | 2019 | 235 | 2.900 |
Why?
|
| Cardiovascular Diseases | 57 | 2024 | 15652 | 2.790 |
Why?
|
| Brain Ischemia | 31 | 2021 | 3008 | 2.550 |
Why?
|
| Intracranial Hemorrhages | 10 | 2020 | 811 | 1.920 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 14 | 2016 | 2277 | 1.750 |
Why?
|
| Cholinesterase Inhibitors | 4 | 2024 | 241 | 1.680 |
Why?
|
| Aspirin | 24 | 2013 | 3136 | 1.640 |
Why?
|
| Headache Disorders | 5 | 2023 | 152 | 1.630 |
Why?
|
| Propensity Score | 11 | 2024 | 1955 | 1.570 |
Why?
|
| Risk Factors | 138 | 2024 | 74954 | 1.420 |
Why?
|
| Women's Health | 14 | 2023 | 2078 | 1.230 |
Why?
|
| Germany | 29 | 2024 | 882 | 1.220 |
Why?
|
| Humans | 380 | 2024 | 768298 | 1.170 |
Why?
|
| Cohort Studies | 84 | 2024 | 41791 | 1.110 |
Why?
|
| Tryptamines | 7 | 2022 | 93 | 1.100 |
Why?
|
| Tension-Type Headache | 3 | 2020 | 76 | 1.080 |
Why?
|
| France | 12 | 2019 | 497 | 1.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 4 | 2010 | 276 | 0.980 |
Why?
|
| Polymorphism, Genetic | 14 | 2014 | 4250 | 0.970 |
Why?
|
| Genetic Predisposition to Disease | 32 | 2022 | 18047 | 0.950 |
Why?
|
| Female | 215 | 2024 | 397050 | 0.940 |
Why?
|
| Middle Aged | 173 | 2024 | 223463 | 0.910 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2010 | 326 | 0.880 |
Why?
|
| Prospective Studies | 94 | 2024 | 54921 | 0.870 |
Why?
|
| Risk Assessment | 39 | 2024 | 24316 | 0.870 |
Why?
|
| Television | 2 | 2016 | 410 | 0.860 |
Why?
|
| Ischemic Attack, Transient | 5 | 2023 | 877 | 0.820 |
Why?
|
| Parkinson Disease | 7 | 2024 | 2893 | 0.810 |
Why?
|
| Cluster Headache | 8 | 2014 | 54 | 0.800 |
Why?
|
| Berlin | 11 | 2024 | 23 | 0.790 |
Why?
|
| Respiratory Insufficiency | 9 | 2022 | 1241 | 0.770 |
Why?
|
| Platelet Transfusion | 1 | 2024 | 301 | 0.750 |
Why?
|
| Aged | 130 | 2024 | 171544 | 0.730 |
Why?
|
| Male | 193 | 2024 | 364870 | 0.730 |
Why?
|
| Population Surveillance | 4 | 2018 | 2598 | 0.710 |
Why?
|
| Intensive Care Units | 8 | 2024 | 3800 | 0.710 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 3 | 2014 | 327 | 0.710 |
Why?
|
| Cognition Disorders | 9 | 2015 | 3985 | 0.710 |
Why?
|
| Vitamin E | 8 | 2012 | 874 | 0.700 |
Why?
|
| Prevalence | 33 | 2023 | 15868 | 0.700 |
Why?
|
| Schools | 6 | 2024 | 1496 | 0.680 |
Why?
|
| Randomized Controlled Trials as Topic | 32 | 2024 | 10377 | 0.680 |
Why?
|
| Thoracic Injuries | 1 | 2022 | 288 | 0.670 |
Why?
|
| Myocardial Infarction | 16 | 2024 | 11515 | 0.660 |
Why?
|
| Smoking | 19 | 2020 | 9109 | 0.660 |
Why?
|
| Positive-Pressure Respiration | 5 | 2018 | 713 | 0.660 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2021 | 1398 | 0.650 |
Why?
|
| Polymorphism, Single Nucleotide | 22 | 2022 | 16027 | 0.650 |
Why?
|
| Vascular System Injuries | 1 | 2022 | 248 | 0.630 |
Why?
|
| Recovery of Function | 5 | 2017 | 2990 | 0.620 |
Why?
|
| Comorbidity | 28 | 2019 | 10588 | 0.610 |
Why?
|
| Coronavirus | 1 | 2020 | 156 | 0.600 |
Why?
|
| Students | 5 | 2024 | 1744 | 0.600 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2021 | 1163 | 0.600 |
Why?
|
| Hyperlipidemias | 4 | 2020 | 773 | 0.600 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2019 | 110 | 0.590 |
Why?
|
| Causality | 8 | 2023 | 1255 | 0.590 |
Why?
|
| Cerebral Veins | 1 | 2019 | 158 | 0.580 |
Why?
|
| Risk | 25 | 2020 | 9635 | 0.580 |
Why?
|
| Body Mass Index | 23 | 2019 | 13050 | 0.580 |
Why?
|
| Analgesics | 5 | 2022 | 1070 | 0.570 |
Why?
|
| Authorship | 1 | 2020 | 289 | 0.570 |
Why?
|
| Cross-Sectional Studies | 26 | 2024 | 26373 | 0.570 |
Why?
|
| Genome-Wide Association Study | 17 | 2022 | 12775 | 0.560 |
Why?
|
| Tuna | 1 | 2016 | 18 | 0.550 |
Why?
|
| Dental Caries | 1 | 2020 | 429 | 0.540 |
Why?
|
| Aged, 80 and over | 60 | 2024 | 59683 | 0.540 |
Why?
|
| Cerebral Hemorrhage | 8 | 2023 | 2653 | 0.540 |
Why?
|
| Proportional Hazards Models | 31 | 2021 | 12557 | 0.530 |
Why?
|
| Obesity | 12 | 2020 | 13082 | 0.530 |
Why?
|
| Incidence | 35 | 2023 | 21544 | 0.530 |
Why?
|
| Medical Records | 3 | 2020 | 1413 | 0.520 |
Why?
|
| Alzheimer Disease | 5 | 2024 | 8747 | 0.520 |
Why?
|
| Seafood | 2 | 2016 | 395 | 0.510 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2022 | 809 | 0.510 |
Why?
|
| Myocardial Revascularization | 3 | 2016 | 796 | 0.500 |
Why?
|
| Dementia | 8 | 2024 | 2728 | 0.500 |
Why?
|
| Pain Measurement | 2 | 2020 | 3579 | 0.490 |
Why?
|
| Alcohol Drinking | 7 | 2016 | 4049 | 0.490 |
Why?
|
| Vascular Diseases | 3 | 2016 | 1161 | 0.490 |
Why?
|
| Cerebrovascular Disorders | 4 | 2019 | 1486 | 0.480 |
Why?
|
| Adult | 102 | 2024 | 223622 | 0.480 |
Why?
|
| National Health Programs | 2 | 2017 | 442 | 0.470 |
Why?
|
| Logistic Models | 26 | 2023 | 13323 | 0.470 |
Why?
|
| Coronary Disease | 6 | 2012 | 5926 | 0.470 |
Why?
|
| Health Status Indicators | 3 | 2017 | 971 | 0.470 |
Why?
|
| Computers, Handheld | 1 | 2016 | 211 | 0.460 |
Why?
|
| Kidney Diseases | 7 | 2011 | 2103 | 0.460 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3118 | 0.460 |
Why?
|
| Follow-Up Studies | 41 | 2021 | 39405 | 0.460 |
Why?
|
| Age Distribution | 10 | 2016 | 2877 | 0.460 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3241 | 0.450 |
Why?
|
| Hypertension | 13 | 2023 | 8615 | 0.440 |
Why?
|
| Tinnitus | 1 | 2016 | 197 | 0.440 |
Why?
|
| Confidence Intervals | 13 | 2021 | 2931 | 0.430 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 1012 | 0.430 |
Why?
|
| Blood Vessels | 2 | 2010 | 1110 | 0.430 |
Why?
|
| Computers | 1 | 2016 | 592 | 0.430 |
Why?
|
| Resuscitation | 1 | 2018 | 679 | 0.430 |
Why?
|
| Odds Ratio | 23 | 2016 | 9681 | 0.430 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 1675 | 0.430 |
Why?
|
| Lipids | 5 | 2020 | 3344 | 0.420 |
Why?
|
| Life Style | 8 | 2021 | 3930 | 0.420 |
Why?
|
| Case-Control Studies | 36 | 2022 | 22292 | 0.410 |
Why?
|
| Pandemics | 9 | 2024 | 8750 | 0.410 |
Why?
|
| Obesity, Morbid | 1 | 2023 | 1306 | 0.400 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 1906 | 0.400 |
Why?
|
| Neuropsychological Tests | 8 | 2024 | 7145 | 0.400 |
Why?
|
| Men's Health | 1 | 2012 | 75 | 0.400 |
Why?
|
| Hospital Mortality | 11 | 2018 | 5367 | 0.400 |
Why?
|
| Mortality | 3 | 2020 | 2917 | 0.400 |
Why?
|
| Caregivers | 1 | 2024 | 2303 | 0.400 |
Why?
|
| Statistics as Topic | 2 | 2016 | 2363 | 0.400 |
Why?
|
| Genetic Loci | 5 | 2022 | 2630 | 0.390 |
Why?
|
| Brain Diseases | 6 | 2018 | 1552 | 0.390 |
Why?
|
| Cardiology | 1 | 2023 | 1701 | 0.390 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2018 | 3743 | 0.390 |
Why?
|
| Educational Status | 5 | 2024 | 2518 | 0.380 |
Why?
|
| Lymphotoxin-alpha | 1 | 2011 | 94 | 0.380 |
Why?
|
| Leukoencephalopathies | 1 | 2014 | 260 | 0.380 |
Why?
|
| Coffee | 2 | 2018 | 597 | 0.370 |
Why?
|
| Health Services Research | 2 | 2020 | 1817 | 0.370 |
Why?
|
| Age Factors | 24 | 2024 | 18472 | 0.370 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 1482 | 0.370 |
Why?
|
| Fibromyalgia | 1 | 2015 | 406 | 0.360 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2013 | 489 | 0.360 |
Why?
|
| United States | 49 | 2024 | 73144 | 0.360 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2011 | 122 | 0.350 |
Why?
|
| Fibrinolytic Agents | 4 | 2009 | 2073 | 0.350 |
Why?
|
| Intraoperative Care | 4 | 2018 | 771 | 0.350 |
Why?
|
| Double-Blind Method | 17 | 2021 | 12457 | 0.350 |
Why?
|
| Biomedical Research | 3 | 2020 | 3464 | 0.340 |
Why?
|
| Self Concept | 1 | 2016 | 1047 | 0.340 |
Why?
|
| Cooking | 1 | 2012 | 312 | 0.340 |
Why?
|
| Food Supply | 1 | 2015 | 544 | 0.340 |
Why?
|
| Epilepsy | 4 | 2024 | 3326 | 0.330 |
Why?
|
| Public Health | 3 | 2018 | 2681 | 0.330 |
Why?
|
| Psychotic Disorders | 1 | 2024 | 3279 | 0.320 |
Why?
|
| Receptors, Neuropeptide | 4 | 2015 | 106 | 0.320 |
Why?
|
| Respiration Disorders | 3 | 2017 | 366 | 0.320 |
Why?
|
| Prostatic Neoplasms | 17 | 2023 | 11220 | 0.320 |
Why?
|
| Proton Pump Inhibitors | 1 | 2014 | 553 | 0.310 |
Why?
|
| Quality of Life | 10 | 2024 | 13499 | 0.310 |
Why?
|
| Exercise | 4 | 2016 | 5947 | 0.310 |
Why?
|
| Cerebral Infarction | 3 | 2011 | 975 | 0.310 |
Why?
|
| Motor Activity | 4 | 2011 | 2720 | 0.310 |
Why?
|
| Blood Pressure | 7 | 2023 | 8541 | 0.310 |
Why?
|
| Vitamins | 4 | 2012 | 1638 | 0.310 |
Why?
|
| Critical Illness | 4 | 2016 | 2755 | 0.300 |
Why?
|
| Sex Distribution | 6 | 2016 | 2281 | 0.300 |
Why?
|
| Sex Characteristics | 3 | 2020 | 2661 | 0.300 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 2215 | 0.300 |
Why?
|
| Adiposity | 1 | 2018 | 1895 | 0.300 |
Why?
|
| Angiotensinogen | 1 | 2008 | 161 | 0.300 |
Why?
|
| Postoperative Complications | 12 | 2021 | 15854 | 0.300 |
Why?
|
| Adiponectin | 4 | 2015 | 1117 | 0.300 |
Why?
|
| Anesthesiology | 1 | 2018 | 1137 | 0.290 |
Why?
|
| Angina Pectoris | 1 | 2012 | 960 | 0.290 |
Why?
|
| Nuts | 1 | 2010 | 265 | 0.290 |
Why?
|
| Databases as Topic | 1 | 2009 | 475 | 0.290 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 948 | 0.290 |
Why?
|
| Prognosis | 21 | 2021 | 30020 | 0.290 |
Why?
|
| Registries | 16 | 2022 | 8378 | 0.290 |
Why?
|
| Sex Factors | 16 | 2022 | 10656 | 0.290 |
Why?
|
| Cholesterol | 8 | 2012 | 2912 | 0.290 |
Why?
|
| Acetaminophen | 3 | 2006 | 556 | 0.290 |
Why?
|
| Feeding Behavior | 2 | 2010 | 3203 | 0.290 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2020 | 190 | 0.290 |
Why?
|
| Brain Infarction | 1 | 2009 | 288 | 0.280 |
Why?
|
| Telomere | 1 | 2013 | 943 | 0.280 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2010 | 340 | 0.280 |
Why?
|
| Models, Theoretical | 2 | 2009 | 3579 | 0.280 |
Why?
|
| Vitamin D | 1 | 2021 | 3311 | 0.280 |
Why?
|
| Aging | 6 | 2011 | 8764 | 0.270 |
Why?
|
| Ascorbic Acid | 4 | 2012 | 658 | 0.270 |
Why?
|
| Suicide, Attempted | 1 | 2015 | 1408 | 0.270 |
Why?
|
| Social Class | 2 | 2024 | 2008 | 0.270 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2006 | 361 | 0.260 |
Why?
|
| Societies, Medical | 2 | 2018 | 3960 | 0.260 |
Why?
|
| Depression | 7 | 2022 | 8241 | 0.260 |
Why?
|
| Triglycerides | 5 | 2019 | 2465 | 0.260 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 662 | 0.260 |
Why?
|
| Length of Stay | 5 | 2018 | 6516 | 0.260 |
Why?
|
| Data Interpretation, Statistical | 4 | 2010 | 2708 | 0.260 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 580 | 0.260 |
Why?
|
| Algorithms | 6 | 2022 | 14154 | 0.260 |
Why?
|
| Mobile Health Units | 2 | 2023 | 93 | 0.260 |
Why?
|
| Receptors, Androgen | 2 | 2010 | 1083 | 0.250 |
Why?
|
| Leptin | 4 | 2015 | 1597 | 0.250 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 299 | 0.250 |
Why?
|
| beta Carotene | 8 | 2010 | 523 | 0.250 |
Why?
|
| Intubation, Intratracheal | 6 | 2018 | 1359 | 0.250 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2006 | 371 | 0.250 |
Why?
|
| Thrombolytic Therapy | 3 | 2023 | 2050 | 0.250 |
Why?
|
| Diabetes Complications | 4 | 2020 | 1322 | 0.250 |
Why?
|
| Genotype | 16 | 2021 | 13038 | 0.250 |
Why?
|
| Physicians | 16 | 2012 | 4614 | 0.250 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 1145 | 0.250 |
Why?
|
| Suicidal Ideation | 1 | 2015 | 1461 | 0.240 |
Why?
|
| Dyspepsia | 1 | 2006 | 116 | 0.240 |
Why?
|
| Neuromuscular Blocking Agents | 3 | 2016 | 132 | 0.240 |
Why?
|
| Models, Statistical | 5 | 2021 | 5099 | 0.240 |
Why?
|
| Stress, Psychological | 2 | 2024 | 4543 | 0.240 |
Why?
|
| Income | 2 | 2024 | 1877 | 0.240 |
Why?
|
| Diet, Mediterranean | 1 | 2012 | 747 | 0.240 |
Why?
|
| Italy | 3 | 2024 | 854 | 0.240 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2024 | 2202 | 0.240 |
Why?
|
| Antioxidants | 5 | 2011 | 1673 | 0.230 |
Why?
|
| Sequence Deletion | 1 | 2009 | 1496 | 0.230 |
Why?
|
| Neoplasms | 11 | 2012 | 22389 | 0.230 |
Why?
|
| Neurology | 1 | 2012 | 786 | 0.230 |
Why?
|
| Treatment Outcome | 25 | 2024 | 65365 | 0.230 |
Why?
|
| Cognition | 3 | 2023 | 7074 | 0.230 |
Why?
|
| Young Adult | 22 | 2024 | 60048 | 0.220 |
Why?
|
| Benzodiazepines | 3 | 2015 | 1139 | 0.220 |
Why?
|
| Adolescent | 27 | 2024 | 89182 | 0.220 |
Why?
|
| Renin-Angiotensin System | 1 | 2008 | 739 | 0.220 |
Why?
|
| Heart Arrest | 4 | 2021 | 1516 | 0.220 |
Why?
|
| Cerebral Arteries | 4 | 2010 | 489 | 0.220 |
Why?
|
| Therapeutics | 1 | 2004 | 113 | 0.220 |
Why?
|
| Common Cold | 1 | 2003 | 63 | 0.220 |
Why?
|
| Health Resources | 1 | 2009 | 950 | 0.210 |
Why?
|
| Severity of Illness Index | 7 | 2016 | 15939 | 0.210 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 924 | 0.210 |
Why?
|
| Genetic Markers | 4 | 2016 | 2604 | 0.210 |
Why?
|
| Chickenpox | 1 | 2023 | 96 | 0.210 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2008 | 577 | 0.210 |
Why?
|
| Delirium | 1 | 2014 | 1695 | 0.210 |
Why?
|
| Research Design | 8 | 2022 | 6209 | 0.210 |
Why?
|
| Diet | 4 | 2014 | 8097 | 0.210 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4874 | 0.210 |
Why?
|
| Nonprescription Drugs | 1 | 2003 | 119 | 0.200 |
Why?
|
| Inpatients | 2 | 2021 | 2569 | 0.200 |
Why?
|
| Probability | 4 | 2023 | 2482 | 0.200 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 2 | 2016 | 42 | 0.200 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 1813 | 0.200 |
Why?
|
| Netherlands | 2 | 2024 | 2274 | 0.200 |
Why?
|
| Weight Gain | 1 | 2012 | 2358 | 0.200 |
Why?
|
| Chronic Disease | 8 | 2020 | 9380 | 0.200 |
Why?
|
| Predictive Value of Tests | 11 | 2016 | 15455 | 0.200 |
Why?
|
| Research Support as Topic | 1 | 2006 | 696 | 0.200 |
Why?
|
| Macular Degeneration | 2 | 2024 | 1016 | 0.190 |
Why?
|
| Erectile Dysfunction | 2 | 2023 | 445 | 0.190 |
Why?
|
| Hospitals | 3 | 2023 | 3905 | 0.190 |
Why?
|
| Editorial Policies | 1 | 2006 | 459 | 0.190 |
Why?
|
| Conflict of Interest | 1 | 2006 | 555 | 0.190 |
Why?
|
| Pneumonia | 4 | 2023 | 2162 | 0.190 |
Why?
|
| Gene Frequency | 5 | 2011 | 3615 | 0.190 |
Why?
|
| Cerebrovascular Circulation | 2 | 2011 | 2736 | 0.190 |
Why?
|
| Carcinoma | 1 | 2012 | 2340 | 0.180 |
Why?
|
| Dental Caries Susceptibility | 1 | 2020 | 28 | 0.180 |
Why?
|
| Critical Care | 4 | 2020 | 2716 | 0.180 |
Why?
|
| Telemedicine | 3 | 2024 | 3107 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 4357 | 0.180 |
Why?
|
| Reproducibility of Results | 10 | 2020 | 20224 | 0.180 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2018 | 117 | 0.180 |
Why?
|
| Urinary Incontinence | 2 | 2023 | 496 | 0.180 |
Why?
|
| Multivariate Analysis | 12 | 2012 | 12092 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 9 | 2011 | 2226 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2019 | 12239 | 0.180 |
Why?
|
| Longitudinal Studies | 11 | 2022 | 14783 | 0.180 |
Why?
|
| Intracranial Thrombosis | 1 | 2021 | 108 | 0.180 |
Why?
|
| Cholesterol, LDL | 4 | 2019 | 2398 | 0.180 |
Why?
|
| Self Efficacy | 1 | 2024 | 643 | 0.170 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 579 | 0.170 |
Why?
|
| Brain | 7 | 2016 | 27452 | 0.170 |
Why?
|
| Vasopressins | 1 | 2021 | 358 | 0.170 |
Why?
|
| Physical Fitness | 2 | 2019 | 744 | 0.170 |
Why?
|
| Pulmonary Edema | 3 | 2018 | 409 | 0.170 |
Why?
|
| Methylprednisolone | 1 | 2021 | 387 | 0.170 |
Why?
|
| Myocardial Ischemia | 2 | 2008 | 2139 | 0.170 |
Why?
|
| Insecticides | 1 | 2021 | 200 | 0.170 |
Why?
|
| Continuity of Patient Care | 3 | 2021 | 1076 | 0.170 |
Why?
|
| Cough | 1 | 2003 | 599 | 0.170 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2018 | 1891 | 0.170 |
Why?
|
| Wounds and Injuries | 2 | 2014 | 2513 | 0.170 |
Why?
|
| Neostigmine | 3 | 2015 | 68 | 0.160 |
Why?
|
| Video Recording | 1 | 2024 | 974 | 0.160 |
Why?
|
| Renal Dialysis | 1 | 2008 | 1802 | 0.160 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2003 | 1039 | 0.160 |
Why?
|
| Health Behavior | 3 | 2008 | 2647 | 0.160 |
Why?
|
| C-Reactive Protein | 6 | 2012 | 3859 | 0.160 |
Why?
|
| Regression Analysis | 4 | 2022 | 6350 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 5 | 2013 | 6084 | 0.160 |
Why?
|
| Health Status | 3 | 2010 | 4094 | 0.160 |
Why?
|
| Pneumococcal Infections | 1 | 2023 | 529 | 0.150 |
Why?
|
| Rehydration Solutions | 1 | 2018 | 43 | 0.150 |
Why?
|
| Hemostasis | 1 | 2021 | 468 | 0.150 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2021 | 309 | 0.150 |
Why?
|
| Defibrillators | 1 | 2018 | 39 | 0.150 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 857 | 0.150 |
Why?
|
| Cholesterol, HDL | 5 | 2019 | 1820 | 0.150 |
Why?
|
| Cardiovascular Agents | 2 | 2021 | 849 | 0.150 |
Why?
|
| Child | 18 | 2024 | 80894 | 0.150 |
Why?
|
| Atherosclerosis | 2 | 2014 | 3431 | 0.150 |
Why?
|
| Patient Participation | 1 | 2007 | 1448 | 0.150 |
Why?
|
| Sumatriptan | 2 | 2016 | 66 | 0.150 |
Why?
|
| Dental Care | 1 | 2020 | 286 | 0.150 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 133 | 0.140 |
Why?
|
| Respiration, Artificial | 3 | 2018 | 2721 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2009 | 217 | 0.140 |
Why?
|
| Surgical Procedures, Operative | 2 | 2021 | 1937 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2010 | 2537 | 0.140 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2018 | 1473 | 0.140 |
Why?
|
| Interdisciplinary Communication | 2 | 2017 | 937 | 0.140 |
Why?
|
| Internet | 1 | 2009 | 3107 | 0.140 |
Why?
|
| Perception | 2 | 2021 | 1206 | 0.140 |
Why?
|
| Comparative Effectiveness Research | 1 | 2022 | 712 | 0.140 |
Why?
|
| Epinephrine | 2 | 2021 | 795 | 0.140 |
Why?
|
| Waist-Hip Ratio | 2 | 2008 | 520 | 0.140 |
Why?
|
| Tea | 1 | 2018 | 290 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 4429 | 0.140 |
Why?
|
| Placebos | 4 | 2021 | 1668 | 0.140 |
Why?
|
| Foramen Ovale, Patent | 2 | 2010 | 210 | 0.130 |
Why?
|
| Survival Analysis | 8 | 2017 | 10117 | 0.130 |
Why?
|
| Early Ambulation | 1 | 2016 | 49 | 0.130 |
Why?
|
| Epidemiologic Methods | 3 | 2011 | 1337 | 0.130 |
Why?
|
| Progestins | 1 | 2018 | 302 | 0.130 |
Why?
|
| Anti-HIV Agents | 2 | 2024 | 4571 | 0.130 |
Why?
|
| Checklist | 1 | 2023 | 843 | 0.130 |
Why?
|
| Family Characteristics | 1 | 2021 | 1003 | 0.130 |
Why?
|
| Contraceptives, Oral | 2 | 2009 | 562 | 0.130 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 2971 | 0.130 |
Why?
|
| Aorta, Thoracic | 1 | 2022 | 1112 | 0.130 |
Why?
|
| Hyperoxia | 1 | 2018 | 261 | 0.130 |
Why?
|
| alpha-Tocopherol | 3 | 2011 | 126 | 0.130 |
Why?
|
| Hypercholesterolemia | 4 | 2015 | 1142 | 0.130 |
Why?
|
| Health Surveys | 6 | 2019 | 4056 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2008 | 2819 | 0.120 |
Why?
|
| Time Factors | 14 | 2020 | 40267 | 0.120 |
Why?
|
| Ketorolac | 1 | 2016 | 95 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 1364 | 0.120 |
Why?
|
| Quadriceps Muscle | 1 | 2016 | 157 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2006 | 1469 | 0.120 |
Why?
|
| Iran | 1 | 2018 | 762 | 0.120 |
Why?
|
| Oral Health | 1 | 2020 | 493 | 0.120 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2011 | 835 | 0.120 |
Why?
|
| Mass Screening | 2 | 2010 | 5451 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2010 | 2911 | 0.120 |
Why?
|
| Climate | 2 | 2023 | 147 | 0.120 |
Why?
|
| Self Report | 4 | 2019 | 3766 | 0.120 |
Why?
|
| Dietary Supplements | 5 | 2012 | 3443 | 0.120 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 984 | 0.120 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2016 | 347 | 0.120 |
Why?
|
| Tidal Volume | 4 | 2018 | 515 | 0.120 |
Why?
|
| Genetic Pleiotropy | 1 | 2015 | 181 | 0.120 |
Why?
|
| Myogenic Regulatory Factors | 2 | 2011 | 102 | 0.120 |
Why?
|
| Glycoproteins | 3 | 2011 | 2204 | 0.110 |
Why?
|
| Rare Diseases | 1 | 2020 | 630 | 0.110 |
Why?
|
| Fluid Therapy | 1 | 2018 | 585 | 0.110 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2007 | 452 | 0.110 |
Why?
|
| HIV Infections | 5 | 2024 | 17575 | 0.110 |
Why?
|
| Caffeine | 1 | 2018 | 702 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 1 | 2022 | 1525 | 0.110 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2017 | 417 | 0.110 |
Why?
|
| Mandatory Programs | 1 | 2014 | 86 | 0.110 |
Why?
|
| Menarche | 1 | 2016 | 538 | 0.110 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2018 | 340 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 9197 | 0.110 |
Why?
|
| Anesthesia, General | 2 | 2018 | 1186 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 489 | 0.110 |
Why?
|
| Disease Progression | 6 | 2015 | 13646 | 0.110 |
Why?
|
| Patient Readmission | 2 | 2018 | 3312 | 0.110 |
Why?
|
| Publishing | 1 | 2020 | 836 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 4300 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2011 | 4637 | 0.110 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 2741 | 0.110 |
Why?
|
| Phenotype | 6 | 2021 | 16716 | 0.110 |
Why?
|
| Physical Therapy Modalities | 1 | 2016 | 533 | 0.100 |
Why?
|
| Atropine | 1 | 2013 | 244 | 0.100 |
Why?
|
| Airway Obstruction | 1 | 2018 | 672 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 36849 | 0.100 |
Why?
|
| Risk Reduction Behavior | 2 | 2011 | 1119 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2168 | 0.100 |
Why?
|
| Hematoma, Subdural | 1 | 2013 | 128 | 0.100 |
Why?
|
| Postmenopause | 1 | 2021 | 2518 | 0.100 |
Why?
|
| Asthma | 2 | 2008 | 6281 | 0.100 |
Why?
|
| Malaria | 1 | 2021 | 1241 | 0.100 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2012 | 145 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 1317 | 0.100 |
Why?
|
| Craniotomy | 1 | 2016 | 747 | 0.100 |
Why?
|
| Anesthetics, Inhalation | 1 | 2017 | 573 | 0.100 |
Why?
|
| Phosphoproteins | 2 | 2011 | 2448 | 0.100 |
Why?
|
| Sarcopenia | 1 | 2016 | 376 | 0.100 |
Why?
|
| Estrogens | 1 | 2018 | 1534 | 0.090 |
Why?
|
| Thrombectomy | 1 | 2016 | 671 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2007 | 1248 | 0.090 |
Why?
|
| Frail Elderly | 1 | 2016 | 775 | 0.090 |
Why?
|
| Europe | 3 | 2018 | 3439 | 0.090 |
Why?
|
| Creatinine | 6 | 2008 | 1915 | 0.090 |
Why?
|
| Bradycardia | 1 | 2013 | 305 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 2016 | 904 | 0.090 |
Why?
|
| Consensus | 2 | 2018 | 3212 | 0.090 |
Why?
|
| Serotonin Receptor Agonists | 2 | 2009 | 151 | 0.090 |
Why?
|
| Massachusetts | 7 | 2021 | 8902 | 0.090 |
Why?
|
| Disabled Persons | 1 | 2020 | 1215 | 0.090 |
Why?
|
| Universities | 1 | 2016 | 1005 | 0.090 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2014 | 708 | 0.090 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 609 | 0.090 |
Why?
|
| Diet Surveys | 1 | 2014 | 1161 | 0.090 |
Why?
|
| Patient Discharge | 3 | 2023 | 3474 | 0.090 |
Why?
|
| Racemases and Epimerases | 1 | 2011 | 114 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 1094 | 0.090 |
Why?
|
| Oxygen | 3 | 2018 | 4273 | 0.090 |
Why?
|
| Receptors, FSH | 1 | 2010 | 29 | 0.090 |
Why?
|
| Hospitalization | 6 | 2023 | 10844 | 0.090 |
Why?
|
| Survivors | 1 | 2021 | 2382 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2012 | 326 | 0.090 |
Why?
|
| Retrospective Studies | 15 | 2022 | 81768 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2011 | 313 | 0.090 |
Why?
|
| Abdomen | 1 | 2016 | 1136 | 0.090 |
Why?
|
| Chromosomes, Human, X | 1 | 2012 | 320 | 0.090 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 6969 | 0.090 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 884 | 0.090 |
Why?
|
| Psychological Tests | 1 | 2012 | 643 | 0.090 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2018 | 997 | 0.090 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2010 | 86 | 0.080 |
Why?
|
| Overweight | 3 | 2012 | 2445 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2011 | 431 | 0.080 |
Why?
|
| Aromatase | 1 | 2010 | 147 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 1664 | 0.080 |
Why?
|
| Inflammation | 1 | 2009 | 10863 | 0.080 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2011 | 308 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2024 | 14736 | 0.080 |
Why?
|
| Validation Studies as Topic | 1 | 2009 | 162 | 0.080 |
Why?
|
| Organ Size | 1 | 2014 | 2268 | 0.080 |
Why?
|
| Trichomonas Infections | 1 | 2009 | 41 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 2433 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6541 | 0.080 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 171 | 0.080 |
Why?
|
| Fishes | 1 | 2012 | 606 | 0.080 |
Why?
|
| Women | 1 | 2011 | 226 | 0.080 |
Why?
|
| Trichomonas vaginalis | 1 | 2009 | 70 | 0.080 |
Why?
|
| Patient Selection | 5 | 2016 | 4265 | 0.080 |
Why?
|
| Muscle Cells | 1 | 2010 | 195 | 0.080 |
Why?
|
| Joints | 1 | 2010 | 324 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 640 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 3776 | 0.080 |
Why?
|
| Alleles | 3 | 2022 | 6892 | 0.080 |
Why?
|
| Hyperacusis | 1 | 2009 | 31 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 21163 | 0.080 |
Why?
|
| Myoblasts | 1 | 2010 | 233 | 0.080 |
Why?
|
| Norway | 1 | 2010 | 501 | 0.080 |
Why?
|
| Electroencephalography | 1 | 2024 | 6317 | 0.080 |
Why?
|
| Endoribonucleases | 1 | 2010 | 230 | 0.080 |
Why?
|
| Forecasting | 1 | 2017 | 2948 | 0.080 |
Why?
|
| Cause of Death | 3 | 2015 | 3728 | 0.080 |
Why?
|
| Selenoproteins | 1 | 2010 | 216 | 0.080 |
Why?
|
| Photophobia | 1 | 2009 | 77 | 0.080 |
Why?
|
| Anxiety | 2 | 2022 | 4675 | 0.080 |
Why?
|
| Antibodies, Protozoan | 1 | 2009 | 251 | 0.080 |
Why?
|
| Mesenchymal Stem Cells | 2 | 2010 | 1666 | 0.080 |
Why?
|
| Muscle Development | 1 | 2010 | 257 | 0.070 |
Why?
|
| C-Peptide | 1 | 2010 | 443 | 0.070 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2010 | 236 | 0.070 |
Why?
|
| Cystatins | 1 | 2007 | 55 | 0.070 |
Why?
|
| Kidney | 1 | 2003 | 7063 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2018 | 2122 | 0.070 |
Why?
|
| Abdominal Fat | 1 | 2009 | 221 | 0.070 |
Why?
|
| Platinum Compounds | 1 | 2008 | 95 | 0.070 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 1764 | 0.070 |
Why?
|
| Oleic Acid | 1 | 2008 | 92 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2009 | 419 | 0.070 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 494 | 0.070 |
Why?
|
| Adipokines | 1 | 2009 | 309 | 0.070 |
Why?
|
| Dermatomycoses | 1 | 2007 | 45 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 453 | 0.070 |
Why?
|
| Health Care Costs | 2 | 2011 | 3267 | 0.070 |
Why?
|
| Onychomycosis | 1 | 2007 | 50 | 0.070 |
Why?
|
| Watchful Waiting | 1 | 2011 | 499 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2024 | 2596 | 0.070 |
Why?
|
| Selenium | 1 | 2010 | 418 | 0.070 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 614 | 0.070 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 286 | 0.070 |
Why?
|
| Chicago | 1 | 2007 | 255 | 0.070 |
Why?
|
| Anesthesia | 1 | 2018 | 1596 | 0.070 |
Why?
|
| Insurance, Physician Services | 1 | 2006 | 23 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 1378 | 0.070 |
Why?
|
| CADASIL | 1 | 2007 | 83 | 0.070 |
Why?
|
| Linoleic Acid | 1 | 2008 | 159 | 0.070 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2007 | 94 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2010 | 962 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2023 | 4748 | 0.070 |
Why?
|
| Epidemiologic Studies | 2 | 2007 | 678 | 0.070 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2006 | 56 | 0.070 |
Why?
|
| Glucose | 1 | 2018 | 4354 | 0.070 |
Why?
|
| DNA Mutational Analysis | 3 | 2009 | 4120 | 0.060 |
Why?
|
| Insurance Claim Reporting | 1 | 2006 | 166 | 0.060 |
Why?
|
| Blood Circulation | 2 | 2017 | 248 | 0.060 |
Why?
|
| Nausea | 1 | 2009 | 682 | 0.060 |
Why?
|
| Observation | 1 | 2007 | 311 | 0.060 |
Why?
|
| Pain | 1 | 2021 | 5102 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2006 | 318 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 4859 | 0.060 |
Why?
|
| Pregnancy Trimester, First | 1 | 2010 | 921 | 0.060 |
Why?
|
| Vomiting | 1 | 2009 | 655 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 3 | 2023 | 5538 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2007 | 681 | 0.060 |
Why?
|
| Mental Disorders | 2 | 2018 | 6876 | 0.060 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 746 | 0.060 |
Why?
|
| Risk Adjustment | 1 | 2009 | 603 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2010 | 1943 | 0.060 |
Why?
|
| Diabetes Mellitus | 5 | 2013 | 5890 | 0.060 |
Why?
|
| Placebo Effect | 1 | 2009 | 518 | 0.060 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2021 | 1037 | 0.060 |
Why?
|
| Alanine | 1 | 2007 | 613 | 0.060 |
Why?
|
| Genetic Testing | 2 | 2009 | 3587 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2009 | 1195 | 0.060 |
Why?
|
| Child, Preschool | 9 | 2022 | 42654 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2014 | 2518 | 0.060 |
Why?
|
| Health Services | 1 | 2009 | 756 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 7861 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2016 | 2106 | 0.060 |
Why?
|
| Cataract | 1 | 2010 | 837 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2007 | 353 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2010 | 790 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2018 | 3836 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2013 | 2763 | 0.060 |
Why?
|
| Disability Evaluation | 3 | 2016 | 1838 | 0.060 |
Why?
|
| Mental Health | 1 | 2018 | 3276 | 0.060 |
Why?
|
| Hospitalists | 1 | 2008 | 298 | 0.060 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2007 | 542 | 0.060 |
Why?
|
| Drainage | 1 | 2010 | 1183 | 0.060 |
Why?
|
| Synovial Membrane | 1 | 2007 | 535 | 0.060 |
Why?
|
| Glycine | 1 | 2007 | 672 | 0.060 |
Why?
|
| Pharmacoepidemiology | 1 | 2007 | 351 | 0.060 |
Why?
|
| Electric Countershock | 2 | 2018 | 534 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 599 | 0.060 |
Why?
|
| Tropical Climate | 1 | 2023 | 35 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 1891 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 646 | 0.060 |
Why?
|
| Poverty | 1 | 2015 | 2721 | 0.050 |
Why?
|
| Penile Erection | 1 | 2023 | 101 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2010 | 2740 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2011 | 1187 | 0.050 |
Why?
|
| China | 1 | 2010 | 2389 | 0.050 |
Why?
|
| Triazoles | 1 | 2009 | 904 | 0.050 |
Why?
|
| Internationality | 1 | 2009 | 1008 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2009 | 1476 | 0.050 |
Why?
|
| Ambulances | 1 | 2023 | 93 | 0.050 |
Why?
|
| Gene Expression | 1 | 2016 | 7595 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 10776 | 0.050 |
Why?
|
| Osteoarthritis | 1 | 2010 | 1070 | 0.050 |
Why?
|
| Neoplasm Staging | 4 | 2011 | 11254 | 0.050 |
Why?
|
| Colombia | 1 | 2023 | 287 | 0.050 |
Why?
|
| Walking | 1 | 2010 | 1201 | 0.050 |
Why?
|
| Adipocytes | 1 | 2009 | 1200 | 0.050 |
Why?
|
| Viral Load | 2 | 2023 | 3398 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2023 | 159 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2010 | 3230 | 0.050 |
Why?
|
| Humidity | 1 | 2023 | 206 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2010 | 1376 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2009 | 2437 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2007 | 757 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2009 | 6238 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 2429 | 0.050 |
Why?
|
| Survival Rate | 4 | 2012 | 12870 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2006 | 1420 | 0.050 |
Why?
|
| Preventive Health Services | 1 | 2006 | 568 | 0.050 |
Why?
|
| Mexico | 2 | 2014 | 767 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2023 | 334 | 0.050 |
Why?
|
| Fibrinopeptide A | 1 | 2021 | 43 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2011 | 1959 | 0.050 |
Why?
|
| Quinazolines | 1 | 2008 | 1374 | 0.050 |
Why?
|
| Drug Costs | 1 | 2009 | 1196 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2011 | 3442 | 0.050 |
Why?
|
| Hospital Costs | 2 | 2018 | 957 | 0.050 |
Why?
|
| Infant | 7 | 2023 | 36512 | 0.050 |
Why?
|
| Prothrombin Time | 1 | 2021 | 117 | 0.050 |
Why?
|
| Factor XI | 1 | 2021 | 40 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2018 | 4819 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2010 | 2593 | 0.050 |
Why?
|
| Factor VII | 1 | 2021 | 139 | 0.050 |
Why?
|
| Linear Models | 2 | 2010 | 5878 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2009 | 7885 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2011 | 1925 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 4908 | 0.040 |
Why?
|
| Polysomnography | 2 | 2018 | 1865 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 1 | 2021 | 204 | 0.040 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2020 | 69 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 1209 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2003 | 993 | 0.040 |
Why?
|
| Integrin beta Chains | 1 | 2020 | 115 | 0.040 |
Why?
|
| Longevity | 1 | 2008 | 1077 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2021 | 279 | 0.040 |
Why?
|
| Prostatectomy | 2 | 2023 | 1841 | 0.040 |
Why?
|
| Sample Size | 1 | 2023 | 848 | 0.040 |
Why?
|
| Quantitative Trait Loci | 2 | 2022 | 2127 | 0.040 |
Why?
|
| Cartilage, Articular | 1 | 2007 | 1104 | 0.040 |
Why?
|
| Electronics | 1 | 2021 | 317 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2016 | 1445 | 0.040 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 1303 | 0.040 |
Why?
|
| Homeostasis | 1 | 2010 | 3349 | 0.040 |
Why?
|
| Pneumococcal Vaccines | 1 | 2023 | 414 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2022 | 525 | 0.040 |
Why?
|
| Emergency Medical Services | 2 | 2023 | 1946 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 809 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 1727 | 0.040 |
Why?
|
| Hypersensitivity | 1 | 2008 | 1172 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2021 | 382 | 0.040 |
Why?
|
| Denmark | 1 | 2021 | 779 | 0.040 |
Why?
|
| Desogestrel | 1 | 2018 | 18 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2021 | 280 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 425 | 0.040 |
Why?
|
| Reference Values | 3 | 2013 | 4941 | 0.040 |
Why?
|
| Hematoma | 1 | 2023 | 767 | 0.040 |
Why?
|
| Factor VIII | 1 | 2021 | 349 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 176 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2021 | 916 | 0.040 |
Why?
|
| Recurrence | 4 | 2020 | 8501 | 0.040 |
Why?
|
| Superior Sagittal Sinus | 1 | 2017 | 15 | 0.040 |
Why?
|
| Quarantine | 1 | 2020 | 187 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2007 | 2025 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 2491 | 0.040 |
Why?
|
| Animals | 8 | 2016 | 169322 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 657 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2010 | 2059 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 6566 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2023 | 764 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2009 | 3334 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2021 | 891 | 0.040 |
Why?
|
| Peptides | 1 | 2009 | 4352 | 0.040 |
Why?
|
| Seasons | 1 | 2023 | 1526 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2010 | 415 | 0.040 |
Why?
|
| Microarray Analysis | 2 | 2011 | 753 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 680 | 0.030 |
Why?
|
| Exhalation | 1 | 2018 | 185 | 0.030 |
Why?
|
| Cortical Spreading Depression | 2 | 2011 | 288 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2021 | 880 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2010 | 4940 | 0.030 |
Why?
|
| Social Support | 1 | 2006 | 2190 | 0.030 |
Why?
|
| Uncertainty | 1 | 2021 | 759 | 0.030 |
Why?
|
| Public Opinion | 1 | 2020 | 486 | 0.030 |
Why?
|
| Nurses | 2 | 2017 | 2494 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2018 | 252 | 0.030 |
Why?
|
| Sweden | 1 | 2019 | 1383 | 0.030 |
Why?
|
| Outpatients | 1 | 2024 | 1603 | 0.030 |
Why?
|
| Austria | 1 | 2016 | 209 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2017 | 513 | 0.030 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2019 | 328 | 0.030 |
Why?
|
| Emergencies | 1 | 2022 | 1219 | 0.030 |
Why?
|
| Boston | 1 | 2009 | 9371 | 0.030 |
Why?
|
| Software | 1 | 2009 | 4452 | 0.030 |
Why?
|
| Workplace | 1 | 2022 | 872 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 5802 | 0.030 |
Why?
|
| Insulin | 1 | 2010 | 6608 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2018 | 540 | 0.030 |
Why?
|
| Telomerase | 1 | 2020 | 752 | 0.030 |
Why?
|
| Mutation | 2 | 2011 | 30230 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2353 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2012 | 2078 | 0.030 |
Why?
|
| India | 1 | 2021 | 2324 | 0.030 |
Why?
|
| Contraception | 1 | 2018 | 362 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 563 | 0.030 |
Why?
|
| Quebec | 1 | 2014 | 139 | 0.030 |
Why?
|
| Atlases as Topic | 1 | 2016 | 248 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2015 | 160 | 0.030 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2015 | 177 | 0.030 |
Why?
|
| Spirometry | 1 | 2018 | 928 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2022 | 1346 | 0.030 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1998 | 746 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2022 | 838 | 0.030 |
Why?
|
| Haplotypes | 2 | 2012 | 2724 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 1998 | 1056 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2024 | 1794 | 0.030 |
Why?
|
| Acute Disease | 2 | 2020 | 7242 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 1088 | 0.030 |
Why?
|
| Social Behavior | 1 | 2020 | 1146 | 0.030 |
Why?
|
| Aphasia | 1 | 2015 | 193 | 0.030 |
Why?
|
| Models, Biological | 1 | 2010 | 9494 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 1343 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2024 | 2784 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2021 | 1389 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2011 | 5168 | 0.030 |
Why?
|
| Melanesia | 1 | 2012 | 13 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 436 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 1585 | 0.030 |
Why?
|
| Health Services for the Aged | 1 | 2015 | 258 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2015 | 900 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2008 | 4847 | 0.030 |
Why?
|
| Thrombosis | 1 | 2006 | 2955 | 0.020 |
Why?
|
| Anesthetics | 1 | 2018 | 525 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 930 | 0.020 |
Why?
|
| Reference Standards | 1 | 2016 | 1013 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 1762 | 0.020 |
Why?
|
| Infant, Newborn | 4 | 2016 | 26410 | 0.020 |
Why?
|
| Calcium Channels, N-Type | 1 | 2011 | 42 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2012 | 128 | 0.020 |
Why?
|
| Pain Threshold | 1 | 2016 | 606 | 0.020 |
Why?
|
| Hyperalgesia | 1 | 2016 | 527 | 0.020 |
Why?
|
| International Cooperation | 1 | 2018 | 1438 | 0.020 |
Why?
|
| Visual Acuity | 2 | 2012 | 2714 | 0.020 |
Why?
|
| Seizures | 1 | 2024 | 3000 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2015 | 1642 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 6404 | 0.020 |
Why?
|
| Health Personnel | 1 | 2005 | 3381 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 9508 | 0.020 |
Why?
|
| Retreatment | 1 | 2012 | 600 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2014 | 1046 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2024 | 6277 | 0.020 |
Why?
|
| Wakefulness | 1 | 2018 | 1283 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2021 | 5311 | 0.020 |
Why?
|
| Premenopause | 1 | 2014 | 1039 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 683 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 3211 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2010 | 862 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 5422 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2009 | 23629 | 0.020 |
Why?
|
| Interleukin-9 | 1 | 2009 | 62 | 0.020 |
Why?
|
| Population Groups | 1 | 2010 | 208 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2016 | 1422 | 0.020 |
Why?
|
| Nursing Homes | 1 | 2016 | 1084 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 5511 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 1174 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2013 | 620 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 6034 | 0.020 |
Why?
|
| Musculoskeletal System | 1 | 2010 | 188 | 0.020 |
Why?
|
| Melanoma | 1 | 2007 | 5705 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 504 | 0.020 |
Why?
|
| Receptors, CCR2 | 1 | 2009 | 216 | 0.020 |
Why?
|
| Genetic Variation | 2 | 2018 | 6606 | 0.020 |
Why?
|
| British Columbia | 1 | 2008 | 240 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 30198 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2007 | 37 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 8562 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2008 | 5948 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 610 | 0.020 |
Why?
|
| Collagen Type X | 1 | 2007 | 16 | 0.020 |
Why?
|
| Collagen Type XI | 1 | 2007 | 21 | 0.020 |
Why?
|
| Collagen Type IX | 1 | 2007 | 20 | 0.020 |
Why?
|
| Observer Variation | 2 | 2005 | 2623 | 0.020 |
Why?
|
| Itraconazole | 1 | 2007 | 43 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT1D | 1 | 2007 | 9 | 0.020 |
Why?
|
| ROC Curve | 1 | 2015 | 3622 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 208 | 0.020 |
Why?
|
| Control Groups | 1 | 2007 | 107 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 1133 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2007 | 36 | 0.020 |
Why?
|
| Aggrecans | 1 | 2007 | 89 | 0.020 |
Why?
|
| Regenerative Medicine | 1 | 2010 | 311 | 0.020 |
Why?
|
| Stem Cells | 2 | 2010 | 3537 | 0.020 |
Why?
|
| Fluconazole | 1 | 2007 | 155 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 3252 | 0.020 |
Why?
|
| Cartilage | 1 | 2010 | 811 | 0.020 |
Why?
|
| Transaminases | 1 | 2007 | 199 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2007 | 151 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2007 | 179 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2013 | 1428 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 628 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2007 | 198 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 1406 | 0.020 |
Why?
|
| Endothelium | 1 | 2009 | 768 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2011 | 697 | 0.020 |
Why?
|
| SOX9 Transcription Factor | 1 | 2007 | 146 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2008 | 558 | 0.020 |
Why?
|
| Cataract Extraction | 1 | 2010 | 465 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2009 | 706 | 0.020 |
Why?
|
| Cystatin C | 1 | 2007 | 272 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2009 | 598 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 1221 | 0.020 |
Why?
|
| Serine | 1 | 2010 | 831 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 525 | 0.020 |
Why?
|
| Cerebellum | 1 | 2013 | 1514 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 1943 | 0.020 |
Why?
|
| Self Medication | 1 | 2006 | 115 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2009 | 637 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2008 | 640 | 0.020 |
Why?
|
| Proteins | 1 | 2020 | 6006 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2010 | 1998 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 13696 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2014 | 1262 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1099 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 1795 | 0.010 |
Why?
|
| Alcoholic Beverages | 1 | 2006 | 266 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 9261 | 0.010 |
Why?
|
| Selection Bias | 1 | 2006 | 360 | 0.010 |
Why?
|
| Pedigree | 1 | 2012 | 4545 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2008 | 876 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2007 | 620 | 0.010 |
Why?
|
| Fasting | 1 | 2010 | 1610 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 13576 | 0.010 |
Why?
|
| Heart Failure | 1 | 2007 | 11860 | 0.010 |
Why?
|
| Diabetic Angiopathies | 1 | 2008 | 806 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2014 | 2754 | 0.010 |
Why?
|
| Edetic Acid | 1 | 2003 | 278 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2008 | 1118 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 3811 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3794 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2007 | 800 | 0.010 |
Why?
|
| Sleep | 1 | 2018 | 4802 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2014 | 3736 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1642 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 2487 | 0.010 |
Why?
|
| Cattle | 1 | 2007 | 3827 | 0.010 |
Why?
|
| Telephone | 1 | 2005 | 630 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 3438 | 0.010 |
Why?
|
| Computational Biology | 1 | 2013 | 3541 | 0.010 |
Why?
|
| Base Sequence | 1 | 2012 | 12421 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 3631 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 4921 | 0.010 |
Why?
|
| Psychometrics | 1 | 2010 | 3069 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 1517 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 2015 | 3247 | 0.010 |
Why?
|
| Genomics | 1 | 2016 | 5916 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 13019 | 0.010 |
Why?
|
| Heterozygote | 1 | 2007 | 2792 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 4043 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2011 | 2083 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2003 | 682 | 0.010 |
Why?
|
| Lung | 1 | 2018 | 10087 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 2884 | 0.010 |
Why?
|
| Prostate | 1 | 2007 | 1780 | 0.010 |
Why?
|
| Transcription Factors | 2 | 2010 | 12166 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8326 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2011 | 2395 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 2257 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 1903 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 2783 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 6319 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 4981 | 0.010 |
Why?
|
| Biopsy | 1 | 2009 | 6808 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 2565 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 2180 | 0.010 |
Why?
|
| Body Weight | 1 | 2007 | 4630 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 3612 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15593 | 0.010 |
Why?
|
| Weight Loss | 1 | 2007 | 2715 | 0.010 |
Why?
|
| Language | 1 | 2005 | 1558 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11117 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5335 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2003 | 1900 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 8730 | 0.010 |
Why?
|
| Endarterectomy, Carotid | 1 | 1999 | 557 | 0.010 |
Why?
|
| Mice | 2 | 2011 | 82004 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 4209 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2010 | 11659 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 8051 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 9433 | 0.010 |
Why?
|
| Apoptosis | 1 | 2009 | 9506 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 12801 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 22355 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1999 | 4842 | 0.000 |
Why?
|